Circular Genomics Secures $15M Series A Financing to Accelerate Clinical Validation of Circular RNAs as Blood Biomarkers for Neurological Disorders

Circular Genomics, a leading developer of circular RNA-based precision medicine tools for neurology and psychiatry, has successfully completed a $15 million Series A financing round. The funding, led by Mountain Group Partners and joined by Poplar Grove Investors, HIP Fund, and the Alzheimer's Drug Discovery Foundation, will be used to expedite the clinical development and commercialization of the company's circRNA biomarker platform for the early detection of Alzheimer's disease.

 The funding aims to address the urgent need for accessible and comprehensive blood-based biomarkers for the earliest detection of neurological disorders, such as Alzheimer's disease. The capital will also support the expansion of the company's team and the launch of its first transformative test for Alzheimer's disease. The financing will target the advancement of various initiatives, particularly the development of circRNA biomarkers as a transformative solution for the early detection of Alzheimer's disease. The company's circRNA platform is designed to capture the complex biology of Alzheimer's disease, offering clinicians actionable insights for better patient care trajectories.

 Furthermore, Circular Genomics aims to introduce a new class of precision neurology diagnostics, enabling the identification of early disease biology and risk assessment, as well as treatment selection and disease monitoring. The innovative technology has the potential to revolutionize Alzheimer's disease patient management by providing accurate, accessible, and comprehensive molecular assessment, even before symptoms appear.

The company's groundbreaking approach has garnered support from prominent investors, recognizing its potential to become a leader in precision neurology diagnostics. Circular Genomics' vision is to reshape the standard of care for the early identification of neurological and psychiatric diseases, such as Alzheimer's disease, Parkinson's disease, major depressive disorder, and bipolar disorder, ultimately leading to more personalized and effective delivery of care.

Read more about the funding here.